Surena F. Matin

Sep 6, 2024 | digitalcommons.library.tmc.edu | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin

Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).

Jul 9, 2024 | urotoday.com | Surena F. Matin

Read the Full Video TranscriptSam Chang: Hi. I'm Sam Chang. I'm a urologist in Nashville, Tennessee, at Vanderbilt University. And I have the honor to really have one of the true leaders in the treatment of upper tract urothelial carcinoma for probably easily over a decade. Dr. Surena Matin is a full professor and attending at the MD Anderson Cancer Center. He really doesn't require any type of introduction.

May 10, 2023 | nature.com | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin |Matthew Campbell |Amado J. Zurita | +4 more

AbstractSitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).